<DOC>
	<DOCNO>NCT03005379</DOCNO>
	<brief_summary>The purpose study determine whether Fecal Microbiota Therapy ( FMT ) effective vs. placebo prevention C. difficile infection recurrence .</brief_summary>
	<brief_title>Microbiota Placebo After Antimicrobial Therapy Recurrent C. Difficile Home ( MATCH )</brief_title>
	<detailed_description>Clostridium difficile infection ( CDI ) one common nosocomial infection increasingly see non-hospitalized patient . Although 90 % patient symptom resolution course standard antimicrobial therapy , subsequent recurrence rate range 15-30 % ( first CDI episode ) 40-50 % ( second subsequent episode ) . Fecal microbiota transplantation ( FMT ) show promise adjunct standard antimicrobial therapy , reduce recurrence among FMT recipient 15 % . The primary study goal ass efficacy FMT prevention subsequent recurrent CDI , administer successful treatment recurrent CDI standard antimicrobial therapy . Secondary goal evaluate , efficacy FMT term CDI severity , duration , safety FMT , event positive study result , establish mechanism provide FMT within VA system . This study enroll 390 participant . Participants randomize ( 1:1 ratio ) FMT placebo , stratify number prior recurrent CDI episodes ( 1 versus &gt; 1 ) . They assess symptom CDI , study outcome treatment-related adverse event 2 , 14 , 28 , 42 , 56 day , month 3 , 4 , 5 6 administration study treatment . The primary outcome recurrent CDI ( definite probable ) death within 56 day randomization . Definite recurrence define : new onset 3 loose watery stool 24 hour 2 consecutive day laboratory confirmation C. difficile stool specimen ; ileus , toxic megacolon colectomy laboratory confirmation . Probable recurrence define identically WITHOUT laboratory confirmation C. difficile ( test negative test ) .</detailed_description>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>One episodes recurrent CDI ( define &gt; 3 loose/watery stools/24h 2 consecutive day PLUS laboratory confirmation C. difficile ; ileus , toxic megacolon PLUS laboratory confirmation C. difficile , occur within 90 day prior CDI episode similar symptom laboratory confirmation ) Resolution improvement symptom recent CDI episode , define longer meet clinical definition CDI 48 hour period treatment , include meet definition initial improvement Within enrollment window : 2 day completion antimicrobial therapy CDI ( allow washout period ) 14 day completion therapy 30 day onset CDI whichever later . Age 18 year Able willing provide inform consent Inability swallow capsule Pregnancy plan pregnant Receipt cytotoxic chemotherapy , intravenous subcutaneous immune globulin , confirm neutropenia ( absolute neutrophil count &lt; 1,000 cells/mL ) within past 3 month Inflammatory bowel disease chronic diarrheal disease/fecal incontinence predate CDI Ongoing antibiotic use current episode CDI Prior FMT Life expectancy &lt; 8 week Anaphylactic food allergy Active enrollment another research study antibiotic , probiotic , FMT without investigator approval Presence ileostomy colostomy Unlikely follow study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FMT</keyword>
	<keyword>recurrent c. difficile</keyword>
	<keyword>infectious disease</keyword>
	<keyword>intestine</keyword>
	<keyword>clinical trial</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>prevention</keyword>
	<keyword>randomize</keyword>
	<keyword>diarrhea</keyword>
	<keyword>fecal microbiota therapy</keyword>
</DOC>